Not sure where that leaves shareholders of AMBS.
Post# of 30066
Posted On: 03/09/2016 7:13:06 PM
Quote:
Not sure where that leaves shareholders of AMBS.
Each of the companies bring something different to the table
Theranostics Health: TheraLink, CLIA Lab, Service Revenue Model and Revenue
Avant: OvaDx and a clean balance sheet. Gregg also mentioned buying a PD Dx asset.
AMDX: MSPrecise, Lympro
All you need is one of these to hit a home run and it's off to the races. If OvaDx and repeat the same results through CLIA, watch out.
The other option for any company is to sell and take in the customary ~10% royalties which isn't that appealing which is why I like this deal.
The replay of the conference call was live as of last night. GC said they are expecting a readout of the Boston CTE work. Be interesting if Lympro can provide some value with CTE in addition to Alzheimer
(7)
(1)